Literature DB >> 22166432

Progressive supranuclear palsy.

Bradley F Boeve1.   

Abstract

Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy which can manifest clinically in a variety of syndromes. In this review, the classic and most common variant syndrome -PSP-Richardson's syndrome (PSP-RS) -is the focus, with the core clinical features, varying cognitive/motor/neuropsychiatric/sleep manifestations, neuropsychological findings, and typical neuroimaging findings all reviewed. Management strategies are also discussed. Of particular interest are the recently commenced clinical trials involving agents which affect key steps in the presumed pathogenesis of the tauopathies. The distinctive and recognizable characteristics of PSP-RS and advent of clinical trials involving potential disease modifying agents underscore the importance of identifying patients with this disorder and encouraging their involvement in trials.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22166432     DOI: 10.1016/S1353-8020(11)70060-8

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  11 in total

1.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Three sib-pairs of autopsy-confirmed progressive supranuclear palsy.

Authors:  Shinsuke Fujioka; Monica Y Sanchez Contreras; Audrey J Strongosky; Kotaro Ogaki; Nathaniel Robb Whaley; Pawel M Tacik; Jay A van Gerpen; Ryan J Uitti; Owen A Ross; Zbigniew K Wszolek; Rosa Rademakers; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2014-11-15       Impact factor: 4.891

Review 3.  Mitochondrial Quality Control Proteases in Neuronal Welfare.

Authors:  Roman M Levytskyy; Edward M Germany; Oleh Khalimonchuk
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-02       Impact factor: 4.147

4.  Tremor in progressive supranuclear palsy.

Authors:  Shinsuke Fujioka; Avi A Algom; Melissa E Murray; Monica Y Sanchez-Contreras; Pawel Tacik; Yoshio Tsuboi; Jay A Van Gerpen; Ryan J Uitti; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2016-03-22       Impact factor: 4.891

Review 5.  Frontotemporal Dementias.

Authors:  Elizabeth C Finger
Journal:  Continuum (Minneap Minn)       Date:  2016-04

6.  Salience driven attention is pivotal to understanding others' intentions.

Authors:  Myrthe G Rijpma; Suzanne M Shdo; Tal Shany-Ur; Gianina Toller; Joel H Kramer; Bruce L Miller; Katherine P Rankin
Journal:  Cogn Neuropsychol       Date:  2021-02       Impact factor: 2.468

7.  An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy.

Authors:  Yun Li; Jason A Chen; Renee L Sears; Fuying Gao; Eric D Klein; Anna Karydas; Michael D Geschwind; Howard J Rosen; Adam L Boxer; Weilong Guo; Matteo Pellegrini; Steve Horvath; Bruce L Miller; Daniel H Geschwind; Giovanni Coppola
Journal:  PLoS Genet       Date:  2014-03-06       Impact factor: 5.917

8.  Impaired perception of surface tilt in progressive supranuclear palsy.

Authors:  Marian L Dale; Fay B Horak; W Geoffrey Wright; Bernadette M Schoneburg; John G Nutt; Martina Mancini
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

Review 9.  Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia.

Authors:  Alberto Benussi; Alessandro Padovani; Barbara Borroni
Journal:  Front Aging Neurosci       Date:  2015-09-01       Impact factor: 5.750

Review 10.  Tau imaging in neurodegenerative diseases.

Authors:  M Dani; D J Brooks; P Edison
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.